Arslan Liaqat/LinkedIn
Aug 8, 2026, 06:51
New Data on Iron Chelation in Thalassemia – Arslan Liaqat
Arslan Liaqat, Doctor of Medicine at BBH Rawalpindi, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in LMJHCR, adding:
“Excited to share the executive summary of our RCT on Deferasirox vs. Deferoxamine in Transfusion-Dependent Thalassemia (published in LMJHCR)!”
Title: Evaluating Effectiveness of Deferasirox Versus Deferoxamine in Improving Clinical Outcomes among Patients with Transfusion-Dependent Thalassemia: A Randomized Controlled Trial
Authors: Muhammad Mohsin Shoukat, Hafiza Khadija Tariq, Fareed Ullah, Muhammad Arslan Liaqat, Areeba Sajjad, Nauman Akhtar
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 8, 2026, 07:13Myth vs Fact – ‘An ITP diagnosis means life stops’ – ITP Support Association
-
Aug 8, 2026, 07:08Andrew Jackson: Clinical Characteristics and Antibiotic Resistance Patterns of Hemodialysis CRBSIs
-
Aug 8, 2026, 07:01Platelets Show Distinct Molecular Changes in Active ITP – JTH
-
Aug 8, 2026, 06:31A New European Programme in Clinical Haemostasis – CRH French Reference Center for Hemophilia Lyon
-
Aug 8, 2026, 05:23Mohsin Naseer։ From Beginner to Published Researcher
-
Aug 8, 2026, 04:50Marc Carrier: Celebrating 20 Years with ASH CRTI
-
Aug 8, 2026, 04:37Megan Adediran: Building Confidence for a Life Beyond Haemophilia
-
Aug 8, 2026, 04:32Megan Kavanaugh Roussos: Airborne Medical Expands Portfolio with WoundClot Advanced Hemostatic Technology
-
Aug 8, 2026, 04:25Maymoon Madkhali։ First Report of a Rare D– – Blood Phenotype in Saudi Arabia